Ticker: BEN

Franklin Templeton (BEN)

Finance Financials Asset Management

Price 32.34

Reco Hold Potential 54 Risk 61 Updated 2026-10-29

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Franklin Templeton is a global investment management firm that offers a range of financial services, including mutual funds, alternative investments, and investment solutions for individuals and institutions. Its core products include equity, fixed income, and multi-asset strategies. The company operates primarily in the asset management segment, generating revenue through management fees, performance fees, and advisory services.

Investment Profile

The investment profile of Franklin Templeton is more aligned with dividend investors due to its substantial dividend yield. The company has a stable revenue stream, making it suitable for those seeking income generation. However, it also presents opportunities for value investors, given its established market position and potential for growth in assets under management.

Category: Finance Sector: Financials Industry: Asset Management Investment style: Balanced Horizon: Medium-term Company type: Blue Chip Company type: Large Cap

Fundamental metrics (experimental) Updated: 2026-10-30

EPS (TTM) — earnings per share for the last 12 months, $: 1.34
Revenue QoQ — quarter-over-quarter revenue growth: -1.4%
EPS surprise: 27.3%
20d volatility: 1.3%
Dividend yield: 6.5%
last ex-date: 2026-03-31

AI recommendation changes

Date	Before	After	Reason
2026-10-23	Sell	Hold	Stable dividend but mixed performance signals.
2026-10-15	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-09-17	Buy	Hold	Weak momentum and fundamentals raise uncertainty.
2026-09-09	Hold	Buy	Strong yield, but mixed fundamentals and momentum.
2026-09-02	Buy	Hold	High yield but negative short-term momentum concerns.
2026-07-27	Hold	Buy	Stable dividend, but mixed momentum signals.
2026-07-14	Buy	Hold	High yield but recent performance raises concerns.
2026-06-27	Hold	Buy	Strong dividend yield and positive momentum indicators.
2026-06-25	Buy	Hold	High yield but recent performance raises concerns.
2026-06-09	Hold	Buy	Strong dividend yield with positive momentum indicators.
2026-06-01	Buy	Hold	Strong dividend yield and positive momentum trends.
2026-05-22	Hold	Buy	Strong dividend yield, but mixed momentum signals.
2026-05-20	Buy	Hold	High yield, but recent performance raises concerns.
2026-05-08	—	Buy	Strong yield, but mixed momentum signals present uncertainty.
2026-05-03	Buy	Hold	Компания показывает сильный рост за последние 20 и 60 дней, а также высокий дивидендный доход. Низкий риск и положительная динамика делают её привлекательной для инвестиций.
2026-04-25	Hold	Buy	Компания показывает стабильный рост за последние 120 дней и имеет высокую дивидендную доходность. Несмотря на небольшие колебания в краткосрочной перспективе, долгосрочные показатели выглядят многообещающе.
2026-04-18	Buy	Hold	Компания показывает положительную динамику цен за последние 20 и 120 дней, а также высокий дивидендный доход. Умеренный риск связан с отрицательной динамикой выручки за последний квартал.
2026-04-09	Hold	Buy	Компания показывает положительную динамику в краткосрочной перспективе, а дивидендная доходность составляет 6.49%, что делает её привлекательной для инвесторов.
2026-03-01	Buy	Hold	Компания имеет стабильный дивидендный доход и положительную динамику на долгосрочном горизонте, но недавние колебания цен и снижение выручки могут вызывать опасения.
2026-02-18	Hold	Buy	Компания показывает стабильную дивидендную доходность и умеренный рост за последние месяцы, но недавнее снижение выручки может указывать на потенциальные риски.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-10-07	UBS	Update	— → 40	31.985
2026-09-25	Morgan Stanley	Target Raised	34 → 35	32.55
2026-08-03	Deutsche Bank	Target Raised	33 → 34	35.39
2026-08-03	Barclays	Target Raised	34 → 36	33.86
2026-07-14	Barclays	Target Raised	31 → 34	32.83
2026-07-10	Evercore ISI	Target Raised	32 → 35	33.84
2026-06-26	Morgan Stanley	Target Raised	31 → 34	32.95
2026-06-08	Evercore ISI	Target Raised	28 → 32	31.495
2026-05-06	Morgan Stanley	Rating Upgraded	— → 31	30.46
2026-04-29	Evercore ISI	Target Raised	27 → 28	29.72
2026-04-29	Goldman Sachs	Target Raised	30.5 → 34	29.46
2026-04-29	Barclays	Rating Upgraded	— → 31	29.46
2026-04-17	Barclays	Target Raised	25 → 26	26.55
2026-04-10	Evercore ISI	Target Lowered	28 → 27	24.945
2026-02-03	Morgan Stanley	Target Raised	21 → 22	27.25
2026-01-15	Barclays	Target Raised	22 → 25	25.63
2025-12-12	Barclays	Target Raised	20 → 22	23.465

News Page 1 of 1

Biotech Sector Remains Attractive to Investors Following Significant Recovery

07/22/2026, 01:37 PM investing review biotech healthcare Franklin Templeton (BEN) State Street Corporation Revolution Medicines

Investors in the biotechnology sector are maintaining a positive outlook following significant gains this year, driven by factors such as potential mergers and acquisitions and a recovery in clinical trials. The performance of key ETFs and specific companies, like Revolution Medicines, highlights the sector's resilience and growth potential.

Sonal Desai of Franklin Templeton Fixed Income Highlights Income Investment Opportunities Amid Fed Uncertainty

07/08/2026, 12:35 PM investing research finance Franklin Templeton (BEN)

Investors can expect high yields in the second half of 2026, driven by Federal Reserve policies and strong economic fundamentals, according to Sonal Desai of Franklin Templeton Fixed Income. The current environment presents various income opportunities across asset classes, particularly in high-yield bonds and structured credit.